据Nkarta报道,现金余额为4.267亿美元,FDA对NKX019的批准,并计划在2024年开始Ntrust-2试验. Nkarta reports $426.7M cash balance, FDA clearance for NKX019, and plans to initiate Ntrust-2 trial in 2024.
Nkarta是一家发展纳戈尔诺-卡拉巴赫细胞疗法的临床阶段生物制药公司,据2024年6月30日报告,现金余额为426.7百万美元,2027年底的业务资金到位。 Nkarta, a clinical-stage biopharmaceutical company developing engineered NK cell therapies, reported a $426.7M cash balance on June 30, 2024, with operations funded into late 2027. 该公司已获得FDA批准,对NKX019进行第二次IND申请,NKX019是自身免疫性疾病的异构疗法候选者,并计划在2024年启动Ntrust-2,用于全身性硬化症,肌肉炎和血管炎的临床试验. The company has received FDA clearance for a second IND application for NKX019, an allogeneic therapy candidate for autoimmune diseases, and plans to initiate Ntrust-2, a clinical trial for systemic sclerosis, myositis, and vasculitis, in 2024. Nkarta还在进行研究者赞助的系统性红斑狼疮试验，并展示了NKX019在复发/难治性非霍奇金淋巴瘤中的随访数据。 Nkarta is also conducting investigator-sponsored trials for systemic lupus erythematosus and has presented follow-up data for NKX019 in relapsed/refractory non-Hodgkin lymphoma.